Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Stock Information for Daxor Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Daxor Corporation

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
Nuwellis Announces Closing of $2.7 Million Public Offering
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
Nuwellis Announces Pricing of $2.7 Million Public Offering
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.